Tocagen (NASDAQ:TOCA) – Research analysts at B. Riley issued their Q2 2018 EPS estimates for Tocagen in a report released on Wednesday, May 16th. B. Riley analyst M. Kumar expects that the company will earn ($0.63) per share for the quarter. B. Riley has a “Buy” rating and a $15.00 price target on the stock. B. Riley also issued estimates for Tocagen’s Q3 2018 earnings at $0.17 EPS, Q4 2018 earnings at ($0.43) EPS, FY2018 earnings at ($1.56) EPS, Q1 2019 earnings at ($0.74) EPS, Q2 2019 earnings at ($0.71) EPS, Q3 2019 earnings at ($0.68) EPS, Q4 2019 earnings at ($0.65) EPS and FY2019 earnings at ($2.61) EPS.
A number of other research analysts also recently weighed in on TOCA. BidaskClub raised shares of Tocagen from a “hold” rating to a “buy” rating in a research report on Tuesday, January 23rd. ValuEngine raised shares of Tocagen from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Finally, Zacks Investment Research raised shares of Tocagen from a “hold” rating to a “buy” rating and set a $15.00 target price for the company in a research report on Wednesday, March 14th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $16.67.
Tocagen (NASDAQ:TOCA) last released its earnings results on Thursday, May 10th. The company reported ($0.65) earnings per share for the quarter. Tocagen had a negative net margin of 109,579.49% and a negative return on equity of 57.09%. The company had revenue of $0.01 million for the quarter.
Several institutional investors have recently added to or reduced their stakes in TOCA. BlackRock Inc. boosted its holdings in Tocagen by 36.4% in the 4th quarter. BlackRock Inc. now owns 1,069,152 shares of the company’s stock worth $10,960,000 after buying an additional 285,396 shares during the period. Lake Street Advisors Group LLC bought a new position in Tocagen in the 4th quarter worth approximately $1,042,000. Artal Group S.A. bought a new position in Tocagen in the 4th quarter worth approximately $1,025,000. Geode Capital Management LLC boosted its holdings in Tocagen by 16.0% in the 4th quarter. Geode Capital Management LLC now owns 90,452 shares of the company’s stock worth $927,000 after buying an additional 12,472 shares during the period. Finally, Russell Investments Group Ltd. boosted its holdings in Tocagen by 107.4% in the 1st quarter. Russell Investments Group Ltd. now owns 81,067 shares of the company’s stock worth $961,000 after buying an additional 41,978 shares during the period. 32.48% of the stock is owned by hedge funds and other institutional investors.
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.